spacer
home > epc > autumn 2003 > clinical trials in asthma
PUBLICATIONS
European Pharmaceutical Contractor

Clinical Trials in Asthma

Respiratory physicians are buzzing about the number of new asthma drugs being developed by a variety of pharmaceutical companies. This is good news for approximately 155 million people worldwide who are affected by the disease. The prevalence of asthma is increasing, generally thought to be associated with spreading urbanisation and exposure to respiratory toxins - including domestic mites, vehicle exhaust and passive smoking.

Asthma is caused by both host risk factors and environmental risk factors. Host factors include genetic predisposition, atopy, airway hyper-responsiveness, gender, race and ethnicity. Environmental factors which increase susceptibility include indoor and outdoor allergens, tobacco smoke, air pollution, respiratory infections - especially viral disease, family size, diet, drugs, obesity and family pets. Recently there has been much research into asthma but the balance between nature, nurture and the changing environment remains poorly understood. We have a long way to go, but there are the beginnings of new therapies for asthma which offer hope for the future.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Alan Davies, Therapeutic Director for Kendle International Inc

Dr Alan Davies qualified at the London Hospital Medical College, obtaining an MB BS in 1975 and an MRCP in 1979. Dr Davies has more than 20 years' experience in drug and device development. He has worked as a University Lecturer in the Medical Schools of Adelaide in Australia, and Manchester and Bristol in the UK. He was awarded an MD in 1988 for his original work on microvascular disease and glycaemic control in children with insulin-dependant diabetes mellitus. Dr Davies joined Novo Laboratories in 1988 and became Head of Clinical Research for Fujisawa GmbH, Munich in the 1990s. Since 2000 he has been Therapeutic Director for Kendle International Inc, one of the world's largest contract research organisations.

spacer
Dr Alan Davies
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI MEA expert:growing domestic manufacturing is creating new opportunities for international Pharma in the Middle East

Abu Dhabi, 5th August 2019: CPhI Middle East expert Emad Shabbir, Director at EMAD Trade House, states favorable conditions and legislative regulations in Saudi Arabia are resulting in a boom of manufacturers and CMOs partnerships with international pharma companies. With the strategic cooperation between regional generic companies and multinational pharma companies, driving increased local production.
More info >>

White Papers

8 Ways To Reduce Tablet Manufacturing Costs

Natoli Engineering Company, Inc.

Itís no surprise that in todayís economy, companies are facing budget cuts across the board. In an effort to address these challenges, this list of 8 Ways to Reduce Tablet Manufacturing Costs was compiled.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement